Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer

Phase 2

Completed

• Conditions: Carcinoma, Non Small Cell Lung

• Registration Number: NCT00191230
• Lead Sponsor: Eli Lilly and Company

Brief Summary

To study the efficacy and tolerability of gemcitabine/platinum chemotherapy in non small cell lung cancer

Detailed Description

Not available

Study Timeline

• Study Start: 2001-09
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-19
• Study Completion: 2006-07
• Status Verified: 2007-01
• Last Update Submitted: 2007-01-24
• Last Update Posted: 2007-01-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Histologically of cytologically confirmed non small cell lung cancer
• No prior chemotherapy or radiation
• No prior malignancy

Exclusion Criteria

• Pregnant or breastfeeding
• Serious concomitant systemic disorder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Complete pathological response

Secondary Outcome Measures

Name	Time	Method
Response rate, disease free survival, toxicity including pulmonary toxicity,operative mortality and quality of life.

Trial Locations

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.; 🇺🇸 Chapel Hill, North Carolina, United States